In a report released on August 17, Jason Kolbert from Dawson James maintained a Buy rating on Cytosorbents (CTSO - Research Report), with a price target of $16.00. The company's shares closed last Friday at $2.00.Kolbert covers the Healthcare sector, focusing on stocks such as Mesoblast, Sorrento Therapeutics, and Can-Fite BioPharma. According to TipRanks, Kolbert has an average return of -1.6% and a 36.32% success rate on recommended stocks. Cytosorbents has an analyst consensus of Moderate Buy, with a price target consensus of $12.50, a 525.00% upside from current levels. In a report released on August 3, H.C. Wainwright also maintained a Buy rating on the stock with a $9.
https://www.tipranks.com/news/blurbs/dawson-james-keeps-their-buy-rating-on-cytosorbents-ctso?utm_source=advfn.com&utm_medium=referral
CytoSorbents (NASDAQ:CTSO)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more CytoSorbents Charts.
CytoSorbents (NASDAQ:CTSO)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more CytoSorbents Charts.